Rubeola Virus Immun (RVI)
Treat sore muscles in horses
- 12ml, 6 doses per vial.
- RVI is a specific immunomodulator agent (IMA) with subvaccination levels of an inactivated rubeola virus that acts to modify the immune and inflammatory responses to alleviate Chronic Myofascial Inflammation (chronic muscle soreness) and its associated problems in the equine.
- For treatment of sore muscles, especially over the back and tendons.
- 12ml vial (6 doses per vial).
RVI is a specific immunomodulator agent (IMA) with subvaccination levels of an inactivated rubeola virus that acts to modify the immune and inflammatory responses to alleviate Chronic Myofascial Inflammation (chronic muscle soreness) and its associated problems in the equine.
- RVI administered subcutaneously, stimulates the same kind of healing afforded by extended rest. But instead of taking months to see results to see results, RVI works in just days.
- RVI acts on a target site in the immune system to restore the proper balance among all its components.
- T-lymphocytes, and especially suppressor T-cells, are the primary control cells of the immune response.
- They function to restrain the B-cells (the antibody producers) and other forms of T-cells from over-responding to insult and from mounting an immune responses to auto (self) antigens.
- Controlled studies prove RVI works within 6 days.
- No side effects have been reported to date.
- RVI is a unique biological immune modulator that can be used during racing or competition because its not a masking agent like ‘Bute.’
- RVI treats only ‘chronic’ inflammatory conditions.
- RVI can be used in conjunction with Phenylbutazone or Banamine to offer the animal relief in the acute phase.
- It can also be administered in conjunction with Adequan for horses with joint problems in addition to muscle soreness.
- DO NOT GIVE RVI IN CONJUNCTION WITH CORTICOSTEROIDS--RVI WILL NOT BE EFFECTIVE.
Because this is a cooler item, it must Ship OVERNIGHT Delivery to insure the integrity of the product. This items ships in a styrofoam cooler with ice packs on Monday-Thursdays (on orders placed before 2:00p.m.)
Click here for our Vaccine Shipping Schedule.
RUBEOLA VIRUS IMMUNOMODULATOR
U.S. Vet. Lic. No.: 385
Active Ingredient(s): An inactivated rubeola virus combined with histamine phosphate in physiological saline. Contains phenol as a preservative. Each 2 mL dose contains 0.1 mcg of neomycin.
Indications: RVI acts to modify the immune and inflammatory responses to alleviate chronic myofascial inflammation (myositis) and its associated problems in the equine.
Dosage and Administration: Inject 2 mL subcutaneously in the neck once a day regardless of weight or age for three (3) to six (6) days or until the desired clinical condition is observed. In severe cases, a daily injection may be required until the horse recovers. Maintenance doses and frequency will depend upon the individual animal but may vary from one (1) dose every other day to one (1) dose a week or even every two (2) weeks. Care should be exercised to ensure that the injection is delivered subcutaneously.
Precaution(s): Store at 35°-45°F (2°-7°C). Protect from freezing.
Caution(s): Rare transient local reactions may occur at the injection site but should subside within 24 hours. For veterinary use only.
Warning(s): Not for use in horses intended for food.
Discussion: T-lymphocytes, including suppressor T-cells, significantly modulate the immune response. Unfortunately these cells are very sensitive to insult, whether from stress, dietary changes, infection, or environmental toxins. These suppressor T-cells function by controlling B-cells (the antibody producers), cytotoxic cells, and helper T-cells from over-responding to insults. Unless controlled, this over response could result in an immune response to auto or self antigens. Evidence indicates an auto immune component to chronic myofascial inflammation and myositis. Studies reflect a decrease in suppressor T-cell function, although not necessarily a decrease in the absolute number of T-cells. RVI acts by specifically modulating suppressor T-cell function in a controlled fashion to allow re-establishment of the normal balance between various subpopulations of T- and B-lymphocytes. This will aid in the healing process leading to the decrease or elimination of myofascial inflammation in the affected animals.
References: Available upon request.
* U.S. Patent No. 4,705,685
Presentation: 12 x 12 mL six dose vials.NAC No.: 1404001.0